Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | ARG1 | P05089 | 2/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.30 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21681172 | 1.00 | MALT1 (0.42) | MALT1ARG1MKNK2IL1BP2RX7 | |
| Hydrochloric Acid SCHEMBL19056470 | 0.98 | MALT1 (0.41) | MALT1ARG1MKNK2IL1BP2RX7 | |
| SCHEMBL35211069 | 0.84 | FUCA1 (0.42) | MALT1ARG1MKNK2IL1BP2RX7 | |
| SCHEMBL27410738 | 0.84 | FUCA1 (0.42) | MALT1ARG1MKNK2IL1BP2RX7 | |
| SCHEMBL12506986 | 0.84 | FUCA1 (0.42) | MALT1ARG1MKNK2IL1BP2RX7 | |
| SCHEMBL22409372 | 0.83 | ARG1 (0.36) | MALT1ARG1IL1BP2RX7 | |
| SCHEMBL21661031 | 0.81 | MALT1 (0.40) | MALT1ARG1MKNK2IL1BP2RX7 | |
| SCHEMBL21661025 | 0.81 | MALT1 (0.40) | MALT1ARG1MKNK2IL1BP2RX7 | |
| SCHEMBL23866584 | 0.80 | MALT1 (0.39) | MALT1ARG1MKNK2IL1BP2RX7 | |
| SCHEMBL23866590 | 0.80 | MALT1 (0.39) | MALT1ARG1MKNK2IL1BP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866426-B2 | Benzothiazole compounds and uses thereof | INCYTE CORPORATION (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102529-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-20210171518-A1 | BENZOTHIAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-10898504-B2 | Substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-26 | — | — | US | disclosed |
| US-10899755-B2 | Benzothiazole compounds and uses thereof | INCYTE CORPORATION (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| US-20200048241-A1 | BENZOTHIAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-02-13 | — | — | US | disclosed |
| EP-2220073-B1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA SRL (IT) | 2014-09-03 | — | — | EP | disclosed |
| US-8268827-B2 | Pyridazinone derivatives as PARP inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-09-18 | — | — | US | disclosed |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA S.R.L. (IT) | 2010-10-14 | — | — | US | disclosed |
| EP-2220073-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063244-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899755-B2 | Benzothiazole compounds and uses thereof | PDXK, PCK1, HIPK1 | MALT1 3283/4885ARG1 4777/4885MKNK2 124/4885 |
| US-20210171518-A1 | BENZOTHIAZOLE COMPOUNDS AND USES THEREOF | PDXK, PCK1, HIPK1 | MALT1 3283/4885ARG1 4777/4885MKNK2 124/4885 |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | MALT1 4299/4885ARG1 65/4885MKNK2 891/4885 |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | MALT1 3473/4885ARG1 2965/4885MKNK2 626/4885 |
| US-20200048241-A1 | BENZOTHIAZOLE COMPOUNDS AND USES THEREOF | PDXK, PCK1, HIPK1 | MALT1 3283/4885ARG1 4777/4885MKNK2 124/4885 |
| US-11866426-B2 | Benzothiazole compounds and uses thereof | PDXK, PCK1, HIPK1 | MALT1 3283/4885ARG1 4777/4885MKNK2 124/4885 |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | MALT1 2694/4885ARG1 1031/4885MKNK2 3148/4885 |
| US-10898504-B2 | Substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | MALT1 4277/4885ARG1 105/4885MKNK2 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.